Detalles de la búsqueda
1.
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs.
Haemophilia
; 29(3): 809-818, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37148500
2.
Gaining consensus around patient risk groups and prognostic profiles to guide CMV management among patients with solid organ transplant: Insights from a Delphi panel with SOT experts.
Clin Transplant
; 37(8): e14905, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36603193
3.
Characterizing female patients with haemophilia A: Administrative claims analysis and medical chart review.
Haemophilia
; 26(3): 520-528, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32268006
4.
Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.
BMC Med Res Methodol
; 19(1): 182, 2019 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31477025
5.
What can we learn from using formal patient-reported outcome instruments to assess pain, functional impairment, anxiety, and depression in US adults with hemophilia?
Eur J Haematol
; 100 Suppl 1: 3-4, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29498785
6.
Patient-reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) study.
Eur J Haematol
; 100 Suppl 1: 14-24, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29498783
7.
Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study.
Eur J Haematol
; 100 Suppl 1: 5-13, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29498784
8.
Correlating S100B with disease course in a case of new onset, acquired thrombotic thrombocytopenic purpura (TTP): Could this be a new predictive biomarker in TTP?
J Clin Apher
; 33(4): 541-545, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29572925
9.
Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange.
Am J Hematol
; 89(7): 695-7, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24668845
10.
Gaining Consensus Around Patient Risk Groups and Prognostic Profiles to Guide CMV Management Among Patients With Allogeneic Hematopoietic Stem Cell Transplant: Insights From a Delphi Panel With Hematopoietic Stem Cell Transplant Experts.
Transplant Proc
; 56(2): 394-408, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38369412
11.
Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
J Manag Care Spec Pharm
; 29(6): 626-634, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37276033
12.
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A.
Expert Rev Pharmacoecon Outcomes Res
; 23(2): 225-230, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36537696
13.
A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
Curr Med Res Opin
; 38(10): 1685-1693, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35880468
14.
Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements.
J Manag Care Spec Pharm
; 28(5): 518-527, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35343812
15.
Estimating Productivity Loss from Breast and Non-Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method.
MDM Policy Pract
; 7(2): 23814683221113846, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35936828
16.
Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel.
J Manag Care Spec Pharm
; 27(8): 996-1008, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33843253
17.
A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors.
J Blood Med
; 12: 913-928, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34707422
18.
Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.
Res Pract Thromb Haemost
; 5(1): 94-103, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33537533
19.
Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A.
J Blood Med
; 12: 935-943, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34754257
20.
Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016.
J Med Econ
; 23(12): 1558-1569, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33161782